ジェイファーマ株式会社 J-Pharma Japanese
About us
Established in December of 2005, J-Pharma’s mission is to help mankind by creating and developing novel pharmaceuticals based upon a human-genomic approach; an approach where people with specific diseases are treated with novel and selective agents. J-Pharma’s intellectual property (IP) embraces the notion that cell membrane transporters are tightly associated to many diseases. In addition to drug molecules that target specific transporters, J-Pharma has discovered several important drug transporters within the human body that may be used to evaluate and optimize pharmacokinetics of new drug candidates. We believe that J-Pharma’s pipelines will lead to new agents and processes (i.e. diagnostic methods) and will increase the quality of life for an ageing population in industrialized countries. J-Pharma’s overall goal is to contribute globally to the maintenance of human health and improve human welfare through the creation of new drugs.
CEO of J-Pharma
Hitoshi Endou, M.D.. Ph.D.

Product Pipeline
Code Area Target Stage
JPH203 Cancer Therapeutics LAT1 PhaseI(ongoing)
JPH211 Cancer Diagnostics LAT1 Clinical trial completion
  JPH211 works as a companion diagnostics with JPH203
JPH367 Hyperuricemia URAT1 Under preclinical
JPH101 Hyperphosphatemia   Preclinical completion
Patented Transporter Portfolio
Material Transporters
L-type amino acid LAT1:SLC7A5,  LAT2:SLC7A8, LAT3:SLC43A1, LAT4:SLC43A2
Uric acid URAT1:SLC22A12, URATv1/GLUT9:SLC2A9, OAT10/URAT2:SLC22A13
Organic anion OAT1:SLC22A5, OAT2:SLC22A7, OAT3:SLC22A8, OAT4:SLC22A11
OAT7:SLC22A9, OATN1:SLC22A13
Testicular carnitine CT2:SLC22A16
Others ASC-1:SLC7A10, Asc-2:SLC7a12, AGT1:SLC7A13
Corporate Information
Corporate name: J-Pharma Co., Ltd.
Founded: December 26, 2005
Business scope: R&D, transporter-targeted therapeutic and diagnostics agents
Directors: Hitoshi Endou M.D., Ph.D (CEO)
Yuko Ikuta
Dai Tsujikawa., MBA
Address: 1-513 Leading Venture Plaza,
75-1 Onocho, Tsurumi-Ku, Yokohama, Kanagawa Pref. 230-0046 Japan
Tel: +81-45-506-1155 Fax: +81-45-506-1156
Origin of the company name “J-Pharma”, We would like to deliver novel drugs to patients in the world by the technology of genomic drug discovery dispatched from Japan, and the abbreviated “J” represents such our hope.
Contact
  info@j-pharma.com
History
1993 Started basic researches on cell membrane transport proteins (transporter) at Kyorin University School of Medicine.
1997-1998 Identified the cancer-specific target molecule of an essential amino acid transporter (LAT1) and acquired its intellectual property right.
2001 Human Cell Systems Inc. was founded in Tokyo to support drug therapy strategy of “Starving tactics for cancer cells” targeting the cancer-specific molecule of LAT1.
Human Cell Systems Inc. is subsidiary of J-Pharma.
2004 Concluded a license agreement with a pharmaceutical company on an anti-hyperuricemic agent, one of our pipelines.
2005 Received a research grant on developing novel anti-pancreatic cancer agents targeting a new molecular from the organization of the Tokyo Joint Development Support Business
--- Research on the strategy of “Starving tactics for cancer cells” against pancreatic cancer.
J-Pharma Co., Ltd. was founded for global strategies of our pipeline development not only in Japan but also worldwide.
2007-2009 Development project of antihyperphosphatemia agent
(Grant from National Institute of Biomedical innovation)
2008-2009 Development of therapeutic agent for gastric scirrhous cancer.
(Grant from New energy and Industrial Technology Development Organization)
2008-2010 Development project of a new molecule probe for PET targeting tumor-specific membrane proteins.
(Grant from Ministry of Education, Culture, Sports, Science and Technology)
2010-2012 Translational Research project on anticancer therapy using LAT1 and its selective inhibitor, JPH203
(Grant from New energy and Industrial Technology Development Organization)
2013-2014 Translational Research Project on "Clinical Study Development of Nobel Anticancer Drug by Amino acid transporter inhibitor"
(Grant from New energy and Industrial Technology Development Organization)
Special Economic Ward Project of City of Yokohama "Development of In Vitro Diagnostic kit for Triple Negative Breast Cancer"
(Grant from City of Yokohama)
2014-2015 Translational Research Project on "Achieving Proof of Concept of JPH203, a Nobel Anticancer Drug, through Clinical Study"
(Grant from New energy and Industrial Technology Development Organization)
Special Economic Ward Project of City of Yokohama "Practical Use of Diagnostic Kit for Triple Negative Breast Cancer"
(Grant from City of Yokohama)
Copyright © 2009.-2014. J-Pharma Co.,Ltd. All Rights Reserved.